Preclinical data suggests that the presence of CD19+ targets is protective against GVHD as tonic signaling through both the CAR and T cell receptor (TCR) promotes an exhaustion phenotype and subsequent apoptosis of alloreactive, GVHD-inducing cells (22). The gene discussed is CD19; the disease is graft versus host disease.